nach oben

Current Treatment Options in Psychiatry

Erschienen in:

01.06.2015 | Post-Traumatic Stress Disorders (T Garacioti and K Chard, Section Editors)

Prazosin for the Treatment of PTSD

verfasst von: Murray A. Raskind, MD

Erschienen in: Current Treatment Options in Psychiatry | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Opinion statement

Prazosin is a generically available central nervous system (CNS) active alpha-1 adrenoreceptor antagonist that has been demonstrated effective in randomized controlled trials (RCTs) for posttraumatic stress disorder (PTSD) trauma nightmares, distressed awakenings, daytime hyperarousal symptoms, and global clinical function. The contribution of increased CNS noradrenergic activity to PTSD pathophysiology and the involvement of the postsynaptic alpha-1 adrenoreceptor in brain systems relevant to PTSD symptomatology provide neurobiologic rationale for prazosin as a PTSD pharmacotherapeutic. This article reviews the clinical observations that led to the development of prazosin therapy for PTSD in combat veterans and the subsequent RCTs that demonstrated prazosin efficacy.

Berridge CW. The locus ceruleus-noradrenergic system and stress: implications for posttraumatic stress disorder. In: Shiromani TKP, LeDoux JE, editors. Posttraumatic stress disorder: basic science and clinical practice. New York: Humana Press; 2009. p. 213–30.

Geracioti Jr TD et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158(8):1227–30.CrossRefPubMed

Mellman TA et al. Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. Biol Psychiatry. 1995;38:174–9.CrossRefPubMed

Bremner JD et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimhine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry. 1997;54:246–54.CrossRefPubMed

Southwick SM et al. Abnormal noradrenergic function in posttaumatic stress disorder. Arch Gen Psychiatry. 1993;50:266–74.CrossRefPubMed

Pietrzak RH et al. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry. 2013;70(11):1199–205.CrossRefPubMedCentralPubMed

Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Hardman J et al., editors. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006.

Lund-Johansen P et al. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents? Cardiology. 1993;83(3):150–9.CrossRefPubMed

Hieble JP, Ruffolo Jr RR. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res. 1996;33(3):145–60.CrossRefPubMed

10.

Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6(3):254–85.CrossRefPubMedCentralPubMed

11.

Pellejero T et al. Effects of methoxamine and alpha-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat. Sleep. 1984;7(4):365–72.PubMed

12.

Cirelli C et al. Modulation of desynchronized sleep through microinjection of alpha 1-adrenergic agonists and antagonists in the dorsal pontine tegmentum of the cat. Pflugers Arch. 1992;422(3):273–9.CrossRefPubMed

13.

Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 1997;11(2):151–62.CrossRefPubMed

14.

Neylan TC et al. Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry. 1998;155(7):929–33.CrossRefPubMed

15.

Ross RJ et al. Sleep disturbance as the hallmark of posttraumatic stress disorder. Am J Psychiatry. 1989;146(6):697–707.CrossRefPubMed

16.

Zayfert C, DeViva JC. Residual insomnia following cognitive behavioral therapy for PTSD. J Trauma Stress. 2004;17(1):69–73.CrossRefPubMed

17.

Ravaris CL et al. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991;11(6):344–50.CrossRefPubMed

18.

Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child. 1988;142(11):1244–7.CrossRefPubMed

19.

Kolb PE, Burns BS, Griffiths S. Propranolol and clonidine in the treatment of the chronic posttraumatic stress disorders of war. In: van der Kolk B, editor. Post traumatic stress disorder: psychological and biological sequelae. Washington DC: American Psychiatric Press; 1984.

20.

Yamada Y et al. Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. J Pharmacokinet Biopharm. 1995;23(2):131–45.CrossRefPubMed

21.

Day TA, Randle JC, Renaud LP. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Res. 1985;358(1–2):171–9.CrossRefPubMed

22.

Medical Economics Company. Physicians desk reference. 62nd ed. Montvale: Medical Economics Company; 2008.

23.

Kiss A, Aguilera G. Participation of alpha 1-adrenergic receptors in the secretion of hypothalamic corticotropin-releasing hormone during stress. Neuroendocrinology. 1992;56(2):153–60.CrossRefPubMed

24.

Birnbaum S et al. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry. 1999;46(9):1266–74.CrossRefPubMed

25.

Southwick SM et al. Noradrenergic alterations in posttraumatic stress disorder. Ann N Y Acad Sci. 1997;821:125–41.CrossRefPubMed

26.

Woodward SH et al. Laboratory sleep correlates of nightmare complaint in PTSD inpatients. Biol Psychiatry. 2000;48(11):1081–7.CrossRefPubMed

27.

Hilakivi I, Leppavuori A. Effects of methoxamine, and alpha-1 adrenoceptor agonist, and prazosin, an alpha-1 antagonist, on the stages of the sleep-waking cycle in the cat. Acta Physiol Scand. 1984;120(3):363–72.CrossRefPubMed

28.

Pickworth WB et al. Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog. Exp Neurol. 1977;57(3):999–1011.CrossRefPubMed

29.

Raskind MA et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–3.CrossRefPubMed

30.••

Raskind MA et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afgahnistan. Am J Psychiatry. 2013;170(9):1003–10. This study provides the strongest evidence for prazosin efficacy for overall PTSD, trauma nightmares, sleep disturbance and global function. This collaborative VA/Department of Defense study is the first ever completed randomized controlled trial of a medication for any behavioral disorder in active duty combat soldiers.CrossRefPubMed

31.

Raskind MA et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928–34.CrossRefPubMed

32.•

Taylor FB et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008;63(6):629–32. This placebo-controlled study objectively demonstrates prazosin improvement of sleep physiology in PTSD.CrossRefPubMedCentralPubMed

33.•

Germain A et al. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military veterans. J Psychosom Res. 2012;72(2):89–96. This study demonstrates both prazosin and a behavioral sleep intervention were effective for sleep disturbance in military veterans.CrossRefPubMedCentralPubMed

34.

Byers MG et al. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 2010;30(3):225–9.CrossRefPubMed

35.

Blake DD et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75–90.CrossRefPubMed

36.

Ajilore O et al. Nightcap: laboratory and home-based evaluation of a portable sleep monitor. Psychophysiology. 1995;32(1):92–8.CrossRefPubMed

37.

van der Helm E et al. REM sleep depotentiates amygdala activity to previous emotional experiences. Curr Biol. 2011;21(23):2029–32.CrossRefPubMedCentralPubMed

38.

Raskind MA. Pharmacologic treatment of PTSD. In: Shiromani PJ, Keane TM, LeDoux JE, editors. Post-traumatic stress disorder. New York: Humana Press; 2009. p. 337–61.CrossRef

39.

Buysse D et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric research and practice. Psychiatry Res. 1989;28(2):193–213.CrossRefPubMed

40.

Calohan J et al. Prazosin treatment of trauma nightmares and sleep disturbance in soldiers deployed in Iraq. J Trauma Stress. 2010;23(5):645–8.CrossRefPubMed

41.

Peskind ER et al. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003;16(3):165–71.CrossRefPubMed

42.

Hermes E, Harpaz-Rotem I, Rosenheck R. Diffusion of prazosin treatment for PTSD. Am J Psychiatry. 2014;171(1):117.CrossRefPubMed

43.

Bernardy NC et al. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):297–303.CrossRefPubMed

44.

Koola MM, Varghese SP, Fawcett JA. High-dose prazosin for the treatment of post-traumatic stress disorder. Ther Adv Psychopharmacol. 2014;4(1):43–7.CrossRefPubMedCentralPubMed

45.

Aurora RN et al. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med. 2010;6(4):389–401.PubMedCentralPubMed

46.

Thompson CE et al. Nonnightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. J Trauma Stress. 2008;21(4):417–20.CrossRefPubMed

47.

Taylor FB et al. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry. 2006;59(7):577–81.CrossRefPubMed

48.

Simpson TL et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33(2):255–63.CrossRefPubMed

49.

Simpson TL et al. Drinking motives moderate daily relationships between PTSD symptoms and alcohol use. J Abnorm Psychol. 2014;123(1):237–47.CrossRefPubMedCentralPubMed

50.

Mayer CL, Huber BR, Peskind E. Traumatic brain injury, neuroinflammation, and post-traumatic headaches. Headache. 2013;53(9):1523–30.PubMedCentralPubMed

51.

Raskind MA et al. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry. 2000;61(2):129–33.CrossRefPubMed

Titel: Prazosin for the Treatment of PTSD
verfasst von: Murray A. Raskind, MD
Publikationsdatum: 01.06.2015
Verlag: Springer International Publishing
Erschienen in: Current Treatment Options in Psychiatry / Ausgabe 2/2015
Elektronische ISSN: 2196-3061
DOI: https://doi.org/10.1007/s40501-015-0040-y

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Preventing Violence in Patients with Schizophrenia

Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

Treatment Strategies for Cannabis Use in Schizophrenia

Current Treatments for Delusional Disorder